FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 306 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... May 10, 2023 Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... May 7, 2021 Enhancements to NCI’s SEER Program Creating New Research Opportunities August 23, 2018 When Cancer Isn’t Your Only Challenge: How I Learned to Cope March 24, 2022 Load more HOT NEWS Development of Secondary T-Cell Cancers After the Use of CAR T-Cells... El cáncer en mi comunidad: Cómo superar las desigualdades en la... Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... Experimental Cancer Drug Metarrestin Targets Metastatic Tumors
